Dr. Wu received her Bachelor of Science in Biology from Yale University and her MD degree from Albert Einstein School of Medicine in 2004. In 2007, she completed her internship and residency in internal medicine at Albert Einstein College of Medicine Long Island Jewish Medical Center. During her hematology/oncolopgy fellowship at the University of Maryland, she developed an interest in clinical and translational research in plasma cell disorders. She joined the facullty at the University of Maryland School of Medicine in 2013.
Dr. Wu's main research interest is multiple myeloma. She is specifically interested in studying the interplay between genetic, environmental, and host factors in the clinical manifestation of disease and response to treatment.
Dr. Wu is board certified in internal medicine, hematology, and medical oncology. Her clinical focus is multiple myeloma and other plasma cell disorders.
Yang WL, Yang-Biggs G, Wu Y, Ye X, Gallos G, Owen RP, Ravikumar TS. Development of cross-resistance between heat and cisplatin or hydroxyurea treatments in FaDu squamous carcinoma cells. J Surg Res. 2003 May 1; 111(1): 143-51.
Wu Y, Goloubeva, Ruehle K, Yanovich S, Rapoport AP, Akpek G, Badros AZ. Outcome of African-American multiple myeloma patients after autologous stem cell transplantation: A single-center experience. Blood (ASH Annual Meeting Abstracts). 2008 Nov; 112: 3327.
Wu Y, Ramani GV, Gai Q, Lemon LC, Baer MR. Rare hemoglobinopathy presenting as progressive dyspnea. Am J Hematol. 2010 May; 85(5): 355-7.
Hussain A, Wu Y, Mirmiran A, DiBiase S, Goloubeva O, Bridges B, Mannuel H, Engstrom C, Dawson N, Amin P, Kwok Y. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostactectomy. Int J Radiat Oncol Biol Phys. 2012 Jan 1; 82(1): 167-74.
Wu Y, Posner MR, Schumaker LM, Nikitakis N, Goloubeva O, Tan M, Lu C, Iqbal S, Lorch J, Sarlis NJ, Haddad RI, Cullen KJ. Novel biomarker panel predicts prognosis in human papillomavirus-negative oropharyngeal cancer: an analysis of the TAX 324 trial. Cancer. 2012 Apr 1; 118(7): 1811-7.